Exc back les sc < 3 cm
CPT code 21930 covers the surgical removal of a skin lesion (growth, mole, or abnormal tissue) from the back that measures less than 3 centimeters in diameter. This involves cutting through the skin and underlying tissue to completely remove the lesion.
This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.
RVU breakdown
Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High
NCCI bundling edits
Loading bundling edits…
Billing tips
Measure the lesion before excision and document the greatest diameter in the operative note; size determines code selection between 21930 (<3cm), 21931 (3cm+), affecting reimbursement significantly
Impact: Incorrect code selection can result in underpayment or overpayment of $200-400 per procedure
Bill in the non-facility setting when performed in office-based surgical suite to capture the higher rate of $490.70 versus $360.99 facility rate
Impact: Increases reimbursement by $129.71 (26.4% higher) per procedure
When multiple lesions are excised, bill the largest/most complex lesion first without modifier, then apply modifier 51 to subsequent excisions to maximize reimbursement
Impact: Proper sequencing can save $50-150 per additional lesion compared to incorrect modifier application
Document subcutaneous involvement clearly; if lesion is only epidermal/dermal without subcutaneous extension, use integumentary codes (11400-11406) instead to avoid downcoding
Impact: Prevents automatic denial and reprocessing delays averaging 45-60 days
Include pathology report confirmation of lesion type and margins in appeal documentation; many payers require histological confirmation for subcutaneous tumor codes
Impact: Improves appeal success rate from 45% to 85% for initially denied claims
For Medicare patients, verify the procedure meets medical necessity criteria with appropriate diagnosis codes (e.g., D21.x for benign neoplasm, C49.x for malignant) rather than symptom-only codes
Impact: Reduces denial rate by approximately 30% and eliminates pre-authorization delays
Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.
Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.
Help build the field knowledge
MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.